Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,706 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all
Completed No phase listed Observational

Observational Study of HIV-associated Neurocognitive Disorder

NCT01966094
View directory record Official record
Conditions
HIV Associated Neurocognitive Disorder, Human Immunodeficiency Virus
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional

Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children

NCT00134602
View directory record Official record
Conditions
HIV Infections
Interventions
Needs assessment followed by tailored intervention
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
5 Years to 12 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Washington D.C., District of Columbia • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE')

NCT04481373
View directory record Official record
Conditions
Human Immunodeficiency Virus, Depression, Anxiety
Interventions
THRIVE, Treatment as Usual
Behavioral · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection

NCT00514605
View directory record Official record
Conditions
HIV Infections
Interventions
Behavioral counseling, HIV-1 Antibody Test Kit
Other · Device
Lead sponsor
bioLytical Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
14
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 10, 2026, 10:46 PM EDT
Completed No phase listed Observational

Immune Correlates of Cardiac Structure and Function

NCT05328713
View directory record Official record
Conditions
Perinatal HIV Infection, Cardiac Fibrosis, Cardiac Inflammation
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
20 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Thalidomide to Treat Oral Lesions in HIV-Infected Patients

NCT00001524
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome, HIV Infection
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

NCT01044654
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
SB-728-T
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

NCT04263142
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 Tablet, GSK3640254 Capsule
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

NCT00002183
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

NCT06032546
View directory record Official record
Conditions
Human Immuno-deficiency Virus (HIV) Disease
Interventions
Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 10, 2026, 10:46 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Botswana Study of UC-781 Vaginal Microbicide

NCT00385554
View directory record Official record
Conditions
HIV Infections
Interventions
UC-781 carbomer gel, 0.1% and 0.25%
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
21 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Atlanta, Georgia • Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

NCT02480894
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 10, 2026, 10:46 PM EDT
Recruiting Phase 2 Interventional

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

NCT05419024
View directory record Official record
Conditions
HIV
Interventions
Acute Treatment Interruption
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults

NCT03784079
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Placebo matching GSK3640254 Mesylate salt
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Bakersfield, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

NCT03227861
View directory record Official record
Conditions
HIV-1
Interventions
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 10, 2026, 10:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome

NCT00342602
View directory record Official record
Conditions
PML, AIDS
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2009 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

NCT02185300
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir Pediatric Granules, Dolutegravir Dispersible Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

NCT01185028
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Nitazoxanide With Pegylated Interferon And Ribavirin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

NCT00000666
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection

NCT03913195
View directory record Official record
Conditions
HIV-1-infection
Interventions
ibalizumab-uiyk
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

Patch Study - Intervention for HIV Positive Smokers

NCT02982772
View directory record Official record
Conditions
Smoking Cessation, HIV
Interventions
Combination Therapy, Standard Care Intervention
Other
Lead sponsor
dr. maria miguez
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

NCT00018031
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Peginterferon alfa-2b, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00001119
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 10, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection

NCT04050735
View directory record Official record
Conditions
HIV-1-infection, Alcohol Drinking
Interventions
Alcohol, ethyl, moderate dose, Placebo
Other
Lead sponsor
Brown University
Other
Eligibility
21 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 10, 2026, 10:46 PM EDT